Table 2.
Pembrolizumab response status based on RECIST and irRECIST for 57 patients with rare cancers
| Primary cancer | Based on RECIST | Based on irRECIST | ||
| Controlled disease (N=20) |
Non-responders (N=37) | Controlled disease (N=24) |
Non-responders (N=33) |
|
| Adrenocortical carcinoma | 5 (25) | 4 (11) | 6 (25) | 3 (9) |
| Carcinoma of unknown primary | 2 (10) | 6 (16) | 4 (12) | 4 (12) |
| Medullary renal carcinoma | 1 (5) | 3 (8) | 1 (4) | 3 (9) |
| Other rare histologies* | 5 (25) | 5 (15) | 5 (20) | 5 (15) |
| Paraganglioma-pheochromocytoma | 3 (15) | 2 (5) | 3 (13) | 2 (6) |
| Penile carcinoma | 0 (0) | 1 (3) | 0 (0) | 1 (3) |
| Small cell malignancies of non-pulmonary origin | 0 (0) | 3 (8) | 1 (4) | 2 (6) |
| Spindle cell sarcoma of retroperitoneum† | 0 (0) | 1 (3) | 0 (0) | 1 (3) |
| Squamous cell carcinoma of the skin | 1 (5) | 3 (8) | 1 (4) | 3 (9) |
| Testicular carcinoma/germ cell tumor | 2 (10) | 7 (19) | 2 (8) | 7 (21) |
| Vascular sarcoma | 1 (5) | 2 (5) | 1 (4) | 2 (6) |
All data are no. of patients (%).
*Vaginal squamous cell carcinoma and others.
†The one case of spindle cell sarcoma of retroperitoneum was initially diagnosed as adrenocortical carcinoma.
irRECIST, immune-related RECIST; RECIST, Response Evaluation Criteria in Solid Tumors.